Here are 1-3 brief analogies for Alpha Teknova (TKNO):

• They're like a specialized Thermo Fisher Scientific, providing essential reagents and media that are the foundational ingredients for biotech research and drug manufacturing.

• Think of them as the "Sysco for biotech labs," supplying the crucial cell culture media, plates, and molecular biology reagents needed to develop drugs and vaccines.

• They're a bit like the "Intel Inside" for biopharmaceutical companies, providing the critical reagents and media that power drug discovery and production.

• Pre-poured media plates: These are ready-to-use plates designed for cell growth and cloning applications.
• Liquid cell culture media and supplements: These products support the expansion of cells in various research and production settings.
• Molecular biology reagents: These reagents are used for manipulating, resuspending, and purifying biological samples.

Alpha Teknova (TKNO) primarily sells to other companies and institutions within the life sciences market, rather than to individuals.

Based on the provided information, its major customer categories include:

• Pharmaceutical and biotechnology companies
• Contract development and manufacturing organizations (CDMOs)
• In vitro diagnostic franchises
• Academic and government research institutions

Specific names of individual customer companies are not disclosed in the provided background information.

Stephen Gunstream, President and CEO

Stephen Gunstream has served as President and Chief Executive Officer of Alpha Teknova since May 2020, and as a director since December 2019. He has over 20 years of experience in sales, marketing, research and development, and general management within the life sciences industry. Before joining Teknova, he held multiple roles at Becton Dickinson & Co. (BD) from June 2015 to December 2019, most recently as Vice President and General Manager of BD Biosciences. From 2008 to 2015, Mr. Gunstream was Chief Commercial Officer at Integrated DNA Technologies, Inc. (IDT), where he was responsible for product development, global sales, and global marketing, and was a co-inventor of several innovative products. Earlier in his career, from 2001 to 2008, he held various product development and business development positions at Applied Biosystems, Inc. (now part of Thermo Fisher Scientific, Inc.). He is a named inventor on 10 issued patents and more than 25 pending patents.

Matthew Lowell, Chief Financial Officer

Matthew Lowell has been Alpha Teknova's Chief Financial Officer since February 2021. Prior to Teknova, he was Vice President of Finance and Treasurer at Varex Imaging Corporation, where he also led business development activities. He also served as Vice President of Finance at Varian Medical Systems, Inc. from April 2013 to December 2016, with responsibilities including financial planning and analysis and business development, and co-led the spin-off of Varex Imaging Corporation from Varian in January 2017. From 2002 to 2013, Mr. Lowell spent over a decade in strategy, business development, and finance roles at Abbott Medical Optics, Inc. and its predecessor, Advanced Medical Optics, Inc. He started his career in investment banking with firms such as NationsBank, N.A., Donaldson, Lufkin & Jenrette, Inc., and Credit Suisse First Boston.

Damon Terrill, General Counsel and Chief Compliance Officer

Damon Terrill serves as the General Counsel and Chief Compliance Officer for Alpha Teknova.

Jennifer Henry, Senior Vice President of Marketing

Jennifer Henry holds the position of Senior Vice President of Marketing at Alpha Teknova.

Ken Gelhaus, Chief Commercial Officer

Ken Gelhaus serves as the Chief Commercial Officer for Alpha Teknova.

Alpha Teknova (NASDAQ: TKNO) faces several key risks inherent to its operations and the life sciences industry.

1. Persistent Operating Losses and Challenges to Achieve Profitability
   Alpha Teknova has a history of incurring operating losses and anticipates that these losses may continue in the future. For the fiscal year ended December 31, 2025, the company reported a net loss of $17.3 million. The path to profitability requires sustained revenue growth and continued margin expansion within a competitive market. Analysts expect the company to remain unprofitable for at least the next three years.
2. Dependence on Customer Research and Development (R&D) Spending and Industry Funding Cycles
   The company's revenues are significantly influenced by the research and development expenditures of its customers, primarily pharmaceutical and biotechnology companies. Fluctuations in R&D budgets, the availability of funding for life sciences, and industry consolidation can directly impact the demand for Alpha Teknova's products. The company has noted "quarter-to-quarter revenue lumpiness" in its Clinical Solutions segment due to the nature of large customer orders and a potential lag between biotech funding and revenue generation.
3. Supply Chain Disruptions, Competition, and Product Quality
   Alpha Teknova is exposed to various external and operational risks, including potential supply chain disruptions, intense competition within the life sciences market, inflationary pressures, rising labor costs, and challenges in securing raw material supplies. Furthermore, the company's success relies on the performance and reliability of its products. Any issues related to product quality or technological reliability could result in lost revenue, damage to its reputation, and reduced market acceptance.

Alpha Teknova (TKNO) is anticipated to drive future revenue growth over the next 2-3 years through several key strategies and market dynamics:

1. Expansion and Commercialization of Clinical Solutions: Alpha Teknova is actively expanding its customer base for clinical products, with a 25% increase in active clinical customers in 2025, reaching 60 active customers. The company supports at least 70 therapies from these customers, with 5 therapies in Phase II or later and 12 in Phase I by the end of 2025. This expansion and the progression of these therapies towards commercialization are expected to translate into significant revenue growth in the next 2-3 years.

2. Investments in Commercial Capabilities: Alpha Teknova plans to invest approximately $2 million annually in its commercial capabilities. These investments are aimed at accelerating revenue growth towards the end of 2026 and into 2027 by expanding the company's presence with customers in attractive market segments.

3. Growth in Lab Essentials (Catalog Products): The Lab Essentials segment, particularly catalog products, has demonstrated strong performance and is expected to continue driving revenue. In the third quarter of 2025, Lab Essentials revenue increased by 16%, primarily due to higher average revenue per customer and an expanded customer count.

4. Operational Efficiencies and Margin Improvement: While not a direct revenue driver, improved operational efficiencies and higher gross margins are crucial for sustainable growth. The company achieved a full-year gross margin of 33.2% in 2025, up from 19.2% in 2024, and anticipates further improvements. Operational initiatives, such as implementing electronic batch records, automating high-throughput dispensing lines, and increasing larger batch size capabilities in 2026, are expected to enhance profitability, allowing for reinvestment and supporting top-line expansion.

5. Potential Collaborations and Acquisitions: Management has identified opportunities for growth through strategic collaborations and acquisitions. Expanding Alpha Teknova's product portfolio and geographic footprint through these avenues is expected to drive additional top-line growth and margin expansion.

Share Issuance

• In June 2021, Alpha Teknova completed its Initial Public Offering (IPO), issuing 6,900,000 shares of common stock at $16.00 per share, resulting in gross proceeds of approximately $110.4 million.
• For the year ended December 31, 2024, the company received $0.1 million from the exercise of stock options and $0.3 million from the issuance of common stock under its employee stock purchase plan.

Capital Expenditures

• In the fourth quarter of 2025, Alpha Teknova invested $348,000 in capital expenditures, primarily funding long-term assets and infrastructure.
• For 2026, the company plans to invest approximately $2 million in commercial capabilities to drive revenue growth.
• Alpha Teknova is continuously investing in processes, establishing a new warehouse/distribution facility, and scaling production to support future commercialization and customer expansion.